Press Release

Schizophrenia Drugs Market Is Expected to Grasp USD 9.48 Billion by 2026, at a CAGR Of 4.3% | Fortune Business Insights

The increasing prevalence of chronic and mental disorder is a key factor expected to enable growth in the global schizophrenia drugs market size, says Fortune Business Insights in a report, titled “Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026.” The global schizophrenia drugs market was valued at USD 6.75 Billion in 2018 and is projected to reach USD 9.48 Billion by 2026, exhibiting a CAGR of 4.3% during the forecast period.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/schizophrenia-drugs-market-101531

Key Segmentation of Schizophrenia Drugs Market:

Schizophrenia Drugs Market Segments by Therapeutic Class

  • Second Generation
  • Third Generation
  • Others

Schizophrenia Drugs Market Segments by Treatment

  • Oral
  • Injectable

Schizophrenia Drugs Market Segments by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content from Schizophrenia Drugs Market

  1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

  1. Executive Summary
  2. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

  1. Key Insights

4.1. Increasing Adoption of Long Acting Injectable (LAIs) as a Form of Treatment

4.2. Prevalence of Schizophrenia Disorders by Key Regions

4.3. New Product Launches

4.4. Pipeline Analysis

4.5. Regulatory Scenario By Key Regions

4.6. Analysis of First Generation Antipsychotics versus Second & Third Generation Antipsychotics

4.7. Overview of R&D Initiatives in Schizophrenia Treatment

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close